J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Johnson & Johnson has been given FDA approval for Akeega, a combination tablet for first-line treatment of adults with BRCA-positive metastatic castration-resistant prostate cancer (mCRPC). The ...

The EMA’s human medicines committee has recommended approval for Akeega, a fixed-dose combination of J&J’s PARP drug Zejula (niraparib) and androgen inhibitor Zytiga (abiraterone acetate), in ...

Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients ...

Akeega combines the active ingredients in GSK’s PARP inhibitor Zejula (niraparib) and J&J’s androgen blocker Zytiga (abiraterone). Given as a dual-action tablet, the therapy works by targeting DNA ...

ASCO 2025 First PARP Inhibitor Combo to Show Benefit in mCSPC Johnson & Johnson's AKEEGA® (niraparib + abiraterone acetate) is the first PARP-based combination to demonstrate statistically significant ...

With smooth performance and nice extras, the 8-inch Legion Tab Gen 3 tablet is hands-down my new favorite mobile gaming device.

Are iPads better than Android tablets? Find out how to choose the best tablet for you and at any budget.

Learn about uses and more of amitriptyline hydrochloride, a prescription tablet that treats depression in adults and some children.

The $60 Fire 7 Tablet holds appeal if you want access to Amazon’s content ecosystem on the cheap, but you should keep your expectations in check.

Recommendations Docetaxel, abiraterone, enzalutamide, or apalutamide, each when administered with androgen deprivation therapy (ADT), represent four separate standards of care for noncastrate ...